65,437 trials
Healthy Volunteers (Meningococcal Infection)
Primary: Infants Groups 1 and 2: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at 30 Days Post Second…
Stage I Bladder Cancer AJCC v8 · Stage II Bladder Cancer AJCC v8 · Stage III Bladder Cancer AJCC v8
Primary: Toxicity for Safety Monitoring (TOX) — 15 percentage of participants
HIV-1
Primary: Cohorts 1 and 2: Pharmacokinetics (PK) of Rilpivirine (TMC278) as Measured by Maximum Observed Plasma Concentration at Steady State (Cmax,ss) — 109; 154; 238 nanograms…
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 12.22; 10.58 Months — p=0.144
Carcinoma, Non- Small Cell Lung
Primary: Disease-free Survival (DFS) — 3.9; 2.0 Months
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Advanced Solid Tumours
Primary: Cohort A (aST): Objective Response Rate (ORR). — 7.14 Percentage of participants
Urinary Tract Infections · Spinal Cord Injuries · Spinal Cord Diseases
Primary: Number of Urinary Tract Infections (UTI) Over Time — 0.53; 0.09 UTI events per person months. — p=<0.0001
Opioid Use Disorder
Primary: Pain Scores Using Numerical Rating Scale (NRS) — 6.62 score on a scale
Postbariatric Hypoglycemia
Primary: Glucose Nadir After Mizagliflozin Dosing — 6.2; 4.0; 17.5; 31.5 mg/dL
PreDiabetes · Prediabetic State
Primary: Number of PCP Visits Where Ppt Was Referred to Diabetes Prevention Program Within 30 Days of Visit — 47; 10 pcp visits
Uterine Leiomyoma · Uterine Fibroids
Primary: Percentage Of Participants Who Maintained MBL Volume Of <80 Milliliters (mL) At Week 76 During The Randomized Treatment Period — 78.43; 15.08 percentage of participants…
Overuse Injury
Primary: Accuracy of the Pitching Detection Algorithm — 98.6 percentage
Primary Ovarian Insufficiency
Primary: Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine — 0.228; 0.673 Z-score